Supreme Court declines to review Oklahoma law regulating PBMs

Supreme Court declines to review Oklahoma law regulating PBMs

There are now conflicting views among appeals courts on how to interpret the issues raised in cases in Arkansas and Oklahoma.

ALBANO: The PBM problem - When regulation undermines access and affordability

Just before the close of the 2025 Louisiana legislative session, a hotly debated bill targeting PBMs – pharmacy benefit managers – was thrown into the arena, which would have barred companies from simultaneously owning PBMs and retail pharmacies. While it ultimately failed to pass, the conversation surrounding PBMs continues. The basic idea behind PBMs is […] The post ALBANO: The PBM problem – When regulation undermines access and affordability …

PBM Transparency: Can It Be More Than a Buzzword?

Employers, some lawmakers and others have criticized pharmacy benefit managers (PBMs), especially the "big three," for having complicated, sometimes hidden practices. The PBMs say they have responded with programs and policies that add transparency to what they do.

U.S. Supreme Court declines review of Oklahoma law regulating PBMs

The U.S. Supreme Court declined to review Oklahoma’s PBM law, leaving in place a ruling that found key parts preempted by ERISA and Medicare Part D. The post U.S. Supreme Court declines review of Oklahoma law regulating PBMs first appeared on The Journal Record.

Supreme Court passes on Oklahoma’s drug middlemen spat

The US Supreme Court on Monday declined to take up a case that could have clarified the extent to which states can regulate pharmacy benefit managers without preempting federal law. The justices denied a petition ...

PCMA supports FTC/DOJ listening session on Big Pharma patent abuse

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) issued a statement of support for today's joint listening session, hosted by the Federal Trade Commission (FTC), the Department of Justice (DOJ), the Department of Health and Human Services (HHS), and the Department of Commerce (DOC). The session focused on “Anticompetitive Conduct by Pharmaceutical Companies Impeding Generic or Biosimilar Competition.”PCMA praised FTC Chair Andr…